TW200716541A - The preparation and use of compounds as protease inhibitors - Google Patents
The preparation and use of compounds as protease inhibitorsInfo
- Publication number
- TW200716541A TW200716541A TW095121030A TW95121030A TW200716541A TW 200716541 A TW200716541 A TW 200716541A TW 095121030 A TW095121030 A TW 095121030A TW 95121030 A TW95121030 A TW 95121030A TW 200716541 A TW200716541 A TW 200716541A
- Authority
- TW
- Taiwan
- Prior art keywords
- compounds
- formula
- disclosed
- methods
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 abstract 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000003908 Cathepsin D Human genes 0.000 abstract 1
- 108090000258 Cathepsin D Proteins 0.000 abstract 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69054305P | 2005-06-14 | 2005-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200716541A true TW200716541A (en) | 2007-05-01 |
Family
ID=37571011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095121030A TW200716541A (en) | 2005-06-14 | 2006-06-13 | The preparation and use of compounds as protease inhibitors |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080113957A1 (zh) |
EP (1) | EP1896406A2 (zh) |
JP (1) | JP2008543846A (zh) |
CN (1) | CN101193859A (zh) |
AR (1) | AR054618A1 (zh) |
CA (1) | CA2610617A1 (zh) |
MX (1) | MX2007016186A (zh) |
PE (1) | PE20070073A1 (zh) |
TW (1) | TW200716541A (zh) |
WO (1) | WO2006138230A2 (zh) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
RU2008100165A (ru) | 2005-06-14 | 2009-07-20 | Шеринг Корпорейшн (US) | Ингибиторы аспартильных протеаз |
CN101198609A (zh) * | 2005-06-14 | 2008-06-11 | 先灵公司 | 天冬氨酰基蛋白酶抑制剂 |
WO2007146225A2 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
AU2007332754A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
EP2200990A1 (en) | 2007-09-06 | 2010-06-30 | Schering Corporation | Gamma secretase modulators |
US8487099B2 (en) | 2007-11-05 | 2013-07-16 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
US8426595B2 (en) | 2007-12-11 | 2013-04-23 | Xianhai Huang | Gamma secretase modulators |
MX2011002705A (es) | 2008-09-11 | 2011-09-09 | Amgen Inc | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso. |
JP5503663B2 (ja) | 2008-11-13 | 2014-05-28 | メルク・シャープ・アンド・ドーム・コーポレーション | ガンマセクレターゼモジュレータ |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
TW201034666A (en) | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
TW201035103A (en) | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
EP2443121A2 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
US20120232108A1 (en) | 2009-06-16 | 2012-09-13 | Xianhai Huang | Gamma secretase modulators |
US20120245158A1 (en) | 2009-06-16 | 2012-09-27 | Xianhai Huang | Gamma secretase modulators |
EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
MX2012010657A (es) | 2010-03-15 | 2013-02-07 | Amgen Inc | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. |
US8921363B2 (en) | 2010-08-05 | 2014-12-30 | Amgen Inc. | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors |
WO2012069428A1 (en) | 2010-11-22 | 2012-05-31 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
EP2643325A1 (en) | 2010-11-23 | 2013-10-02 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
EP2673279A1 (en) | 2011-02-07 | 2013-12-18 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
US8962859B2 (en) | 2011-02-15 | 2015-02-24 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
CN104270945B (zh) | 2012-03-19 | 2017-03-29 | 巴克老龄化研究所 | App特异性bace抑制剂(asbi)及其用途 |
WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
KR102220259B1 (ko) | 2013-02-12 | 2021-02-25 | 버크 인스티튜트 포 리서치 온 에이징 | Bace 매개 app 처리과정을 조절하는 히단토인 |
US20220267280A1 (en) * | 2019-08-16 | 2022-08-25 | Purdue Research Foundation | Small molecule stimulators of the core particle of the proteasome |
CN114702591B (zh) * | 2022-05-17 | 2022-09-23 | 诺赛联合(北京)生物医学科技有限公司 | 成体细胞衍生的类器官制备技术 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1168896B (de) * | 1962-06-16 | 1964-04-30 | Hoechst Ag | Verfahren zur Herstellung von N, N-disubstituierten Amidinen |
DE2235177A1 (de) * | 1972-07-18 | 1974-02-07 | Bayer Ag | Verfahren zur herstellung von lactamhydrazonen aromatischer systeme |
WO2003074467A2 (en) * | 2002-03-04 | 2003-09-12 | Procyon Biopharma Inc. | Urea derivatives as hiv aspartyl protease inhibitors |
MY149978A (en) * | 2003-12-15 | 2013-11-15 | Merck Sharp & Dohme | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
BRPI0512213A (pt) * | 2004-06-16 | 2008-02-19 | Wyeth Corp | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto |
AU2005264917A1 (en) * | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
-
2006
- 2006-06-12 JP JP2008516986A patent/JP2008543846A/ja active Pending
- 2006-06-12 US US11/451,194 patent/US20080113957A1/en not_active Abandoned
- 2006-06-12 CN CNA2006800208944A patent/CN101193859A/zh active Pending
- 2006-06-12 CA CA002610617A patent/CA2610617A1/en not_active Abandoned
- 2006-06-12 AR ARP060102463A patent/AR054618A1/es not_active Application Discontinuation
- 2006-06-12 WO PCT/US2006/022849 patent/WO2006138230A2/en active Application Filing
- 2006-06-12 MX MX2007016186A patent/MX2007016186A/es unknown
- 2006-06-12 EP EP06772948A patent/EP1896406A2/en not_active Withdrawn
- 2006-06-13 TW TW095121030A patent/TW200716541A/zh unknown
- 2006-06-13 PE PE2006000663A patent/PE20070073A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2610617A1 (en) | 2006-12-28 |
PE20070073A1 (es) | 2007-03-08 |
AR054618A1 (es) | 2007-07-04 |
EP1896406A2 (en) | 2008-03-12 |
JP2008543846A (ja) | 2008-12-04 |
WO2006138230A3 (en) | 2007-04-12 |
WO2006138230A2 (en) | 2006-12-28 |
CN101193859A (zh) | 2008-06-04 |
MX2007016186A (es) | 2008-03-07 |
US20080113957A1 (en) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200716541A (en) | The preparation and use of compounds as protease inhibitors | |
TW200716574A (en) | The preparation and use of compounds as aspartyl protease inhibitors | |
HRP20130664T1 (en) | Heterocyclic aspartyl protease inhibitors | |
MY149183A (en) | Heterocyclic aspartyl protease inhibitors | |
WO2006065277A3 (en) | Heterocyclic aspartyl protease inhibitors | |
WO2006138265A3 (en) | Heterocyclic aspartyl protease inhibitors, preparation and use thereof | |
MX2009006227A (es) | Inhibidores de aspartil proteasa que contienen un sistema de anillo triciclico. | |
TW200716644A (en) | Aspartyl protease inhibitors | |
SG162790A1 (en) | Aspartyl protease inhibitors | |
WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
WO2005037825A3 (en) | Protein kinase inhibitors | |
WO2007120647A3 (en) | Compositions useful as inhibitors of voltage-gated sodium channels | |
WO2007050721A3 (en) | Heterocyclic aspartyl protease inhibitors | |
TW200716645A (en) | Macrocyclic heterocyclic aspartyl protease inhibitors | |
WO2004087699A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
WO2004087698A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
DE602004007239D1 (de) | 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN | |
WO2007143523A8 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
WO2005040171A8 (en) | Pyrazolo and imidazo-pyrimidine derivatives | |
PL1682528T3 (pl) | Pochodne benzo[b][1,4]dioksepiny | |
EP1688420A4 (en) | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR | |
MY133527A (en) | Isoquinoline derivatives | |
WO2004060862A3 (en) | Compounds having prolyl oligopeptidase inhibitory activity | |
TW200619203A (en) | Heterocyclic aspartyl protease inhibitors |